The global hyaluronic acid raw material market size was estimated at USD 6.61 billion in 2022 and is projected to reach USD 10.8 billion by 2030, growing at a CAGR of 6.5% from 2023 to 2030. The market growth is primarily driven by the rapidly aging global population, which has increased the demand for anti-aging and joint health products, as well as by the development of technologically advanced formulations that allow for localized and targeted drug delivery. These innovations have enhanced the therapeutic efficacy of hyaluronic acid across various medical and cosmetic applications, thereby fueling overall market expansion.

Moreover, the rising number of aesthetic and cosmetic procedures performed across major economies such as the U.S., Brazil, China, Japan, and South Korea is playing a key role in propelling market growth. These countries have seen a surge in minimally invasive aesthetic treatments that utilize hyaluronic acid-based fillers and injectables for facial rejuvenation and contouring. The increasing awareness regarding appearance enhancement, coupled with the growing acceptance of aesthetic procedures among both men and women, continues to positively influence product demand.

The COVID-19 pandemic initially had a notable adverse impact on the hyaluronic acid market, particularly during the early stages of the outbreak. Although hyaluronic acid is widely used in elective medical and aesthetic procedures, the suspension or postponement of non-essential surgeries and treatments by patients and healthcare providers to minimize infection risks resulted in a temporary decline in demand. Consequently, the sector experienced a reduction in overall revenue during this period.

In addition, the consumption of hyaluronic acid-based dietary supplements also declined significantly during the pandemic. For instance, Anika Therapeutics, a leading manufacturer of hyaluronic acid products, reported a 24% decrease in the usage of its supplements for osteoarthritis treatment. The reduced consumer focus on elective healthcare and wellness products contributed to this downturn.

However, as pandemic restrictions were gradually lifted and healthcare systems resumed normal operations, elective procedures—especially injection-based treatments—regained popularity. Patients increasingly preferred non-surgical, minimally invasive options such as dermal fillers and joint injections over traditional surgical interventions. This post-pandemic recovery trend is expected to revitalize the demand for hyaluronic acid-based products, supporting market growth in the forecast period.

Key Market Trends & Insights:

• North America dominated the hyaluronic acid raw material market in 2022, accounting for the largest revenue share of 40.9%. This strong regional performance can be attributed to the high adoption of advanced healthcare technologies, growing awareness about aesthetic treatments, and increased demand for anti-aging and orthopedic solutions. In addition, the presence of leading market players, favorable reimbursement policies, and a well-established healthcare infrastructure have further strengthened the region’s position as a major contributor to global revenue.

• On the other hand, the Asia Pacific region is projected to register the fastest compound annual growth rate (CAGR) of 9.0% during the forecast period. Factors such as rapidly expanding medical tourism, rising disposable income levels, and increasing awareness of cosmetic and wellness treatments are driving this growth. Moreover, the surge in healthcare investments, coupled with the growing focus on aesthetic enhancement among younger populations in countries like China, Japan, South Korea, and India, is anticipated to further accelerate regional demand.

• By application, the orthopedics segment led the market in 2022, capturing the largest revenue share of 39.7%. The segment’s dominance is primarily due to the rising prevalence of joint disorders, including osteoarthritis and rheumatoid arthritis, and the growing use of hyaluronic acid-based injections for pain management and improved joint mobility. Additionally, the increasing preference for minimally invasive treatment options and the expanding elderly population suffering from degenerative bone diseases have further supported segment growth.

• In terms of source, the non-animal segment accounted for the largest revenue share of 96.8% in 2022. This overwhelming dominance is attributed to the rising preference for non-animal-derived hyaluronic acid due to its lower risk of allergic reactions, better biocompatibility, and ethical acceptability compared to animal-based alternatives. The availability of advanced microbial fermentation technologies has also made large-scale production of non-animal hyaluronic acid more efficient and sustainable.

• By grade, the pharmaceutical segment held the largest revenue share of 72.1% in 2022, making it the leading category. The high share can be linked to the extensive use of hyaluronic acid in drug formulation, wound healing, ophthalmology, and orthopedic applications. Its wide acceptance in the medical field, supported by regulatory approvals and ongoing research in regenerative medicine, continues to strengthen its dominance in the pharmaceutical-grade segment.

Order a free sample PDF of the Hyaluronic Acid Raw Material Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 6.61 Billion

• 2030 Projected Market Size: USD 10.8 Billion

• CAGR (2023-2030): 6.5%

• North America: Largest market in 2022

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Product launches, increased investments in research and development (R&D), and the continuous expansion of product portfolios are among the key strategies adopted by major players to strengthen their position in the global hyaluronic acid market. These initiatives allow companies to enhance product innovation, cater to evolving consumer needs, and gain a competitive edge through technological advancements and diversified applications.

For instance, in June 2023, Galderma, a well-known provider of skincare and dermatological treatment products, announced the approval of Restylane Eyelight by the U.S. Food and Drug Administration (FDA). This regulatory approval authorizes the use of Restylane Eyelight for the treatment of undereye hollows, commonly referred to as dark shadows, in adults aged 21 years and above. The product represents an important advancement in the aesthetic medicine segment, addressing one of the most common aesthetic concerns related to facial fatigue and aging.

Restylane Eyelight is an under-eye dermal filler composed of hyaluronic acid (HA) and stands out in the U.S. market due to its incorporation of NASHA Technology—a proprietary formulation designed to provide a firmer gel texture with controlled water absorption. This technology allows for precise placement of the filler to restore volume loss in the undereye area, ensuring natural-looking and long-lasting results. The product’s introduction further strengthens Galderma’s already extensive dermal filler portfolio, demonstrating the company’s ongoing commitment to innovation in the aesthetic and dermatological care markets.

Key Players

• AbbVie Inc.

• Salix Pharmaceuticals

• Lifecore Biomedical, Inc.

• Sanofi

• Anika Therapeutics, Inc.

• Zimmer Biomet

• Smith+Nephew

• LG Chem

• Maruha Nichiro Corporation

• Ferring B.V.

• SEIKAGAKU CORPORATION

• F. Hoffmann-La Roche Ltd.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the hyaluronic acid raw material market is poised for robust growth over the coming years, driven by demand from both medical and cosmetic sectors. Aging populations, rising prevalence of joint and ocular disorders, and growing adoption of aesthetic procedures are key growth catalysts. Innovations in formulation and localized delivery are contributing to product differentiation and expanded applications. Moreover, the dominance of non-animal sources and pharmaceutical-grade material underscores industry trends toward safety, regulatory compliance, and high purity standards. Overall, the market outlook is favorable, with expanding opportunities across geographies and end-use verticals.